IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC

IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC

Abstract Background Most small cell lung cancer (SCLC) patients exhibit resistance to immune checkpoint inhibitors (ICIs) and demonstrate downregulation of major histocompatibility complex class I (MHC-I) molecules. This study aimed to elucidate the regulatory mechanisms underlying MHC-I expression...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanan Cui, Tianyu Qiu, Jiale Wang, Xinyu Liu, Libo Luo, Jizhong Yin, Xinxin Zhi, Wanying Wang, Gaohua Feng, Chunyan Wu, Zhikai Zhao, Hua Zhang, Fei Li, Fengying Wu, Shengxiang Ren
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Molecular Cancer
Subjects:
Small cell lung cancer
Immunotherapy
MHC-I
IFITM3
Online Access:https://doi.org/10.1186/s12943-025-02383-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12943-025-02383-x

Similar Items